• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Acute Myeloid Leukemia After Radium-223 Therapy: Case Report.

作者信息

Varkaris Andreas, Gunturu Krishna, Kewalramani Tarun, Tretter Christopher

机构信息

Department of General Internal Medicine, Lahey Clinic, Burlington, MA; Tufts Medical School, Tufts University, Medford, MA.

Department of Oncology, Lahey Clinic, Burlington, MA; Tufts Medical School, Tufts University, Medford, MA.

出版信息

Clin Genitourin Cancer. 2017 Aug;15(4):e723-e726. doi: 10.1016/j.clgc.2016.11.002. Epub 2016 Dec 1.

DOI:10.1016/j.clgc.2016.11.002
PMID:28024949
Abstract
摘要

相似文献

1
Acute Myeloid Leukemia After Radium-223 Therapy: Case Report.镭-223治疗后发生急性髓系白血病：病例报告
Clin Genitourin Cancer. 2017 Aug;15(4):e723-e726. doi: 10.1016/j.clgc.2016.11.002. Epub 2016 Dec 1.
2
Acute Promyelocytic Leukemia After Treatment of Metastatic Castration-Resistant Prostate Cancer With Radium-223.用镭-223治疗转移性去势抵抗性前列腺癌后发生的急性早幼粒细胞白血病
Clin Genitourin Cancer. 2017 Jun;15(3):e501-e502. doi: 10.1016/j.clgc.2016.12.028. Epub 2016 Dec 29.
3
Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial.镭-223 二氯化物在有或无先前多西他赛治疗的去势抵抗性前列腺癌和有症状骨转移患者中的疗效和安全性：来自随机、双盲、III 期 ALSYMPCA 试验的预设亚组分析。
Lancet Oncol. 2014 Nov;15(12):1397-406. doi: 10.1016/S1470-2045(14)70474-7. Epub 2014 Oct 17.
4
Radium-223 international early access program: results from the Spanish subset.镭-223 国际早期准入计划：西班牙子研究集结果。
Future Oncol. 2018 Jan;14(1):41-50. doi: 10.2217/fon-2017-0297. Epub 2017 Dec 13.
5
Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Radium-223 is the preferred therapy in bone-predominant symptomatic metastatic castration-resistant prostate cancer.反驳观点：在有症状的转移性去势抵抗性前列腺癌中，多西他赛和镭-223应首先使用哪一种？镭-223是骨转移为主的有症状转移性去势抵抗性前列腺癌的首选治疗方法。
Clin Adv Hematol Oncol. 2015 May;13(5):293-8.
6
DNA Repair Pathway Alterations in Metastatic Castration-resistant Prostate Cancer Responders to Radium-223.转移性去势抵抗性前列腺癌对镭-223有反应者的DNA修复途径改变
Clin Genitourin Cancer. 2018 Apr;16(2):106-110. doi: 10.1016/j.clgc.2017.11.009. Epub 2017 Dec 6.
7
Lymph Node Response in a Patient With Metastatic Castration-resistant Prostate Cancer Treated With Radium-223.用镭-223治疗的转移性去势抵抗性前列腺癌患者的淋巴结反应
Clin Genitourin Cancer. 2018 Apr;16(2):e397-e401. doi: 10.1016/j.clgc.2017.10.024. Epub 2017 Nov 7.
8
Hematologic Toxicity From Radium-223 Therapy for Bone Metastases in Castration-Resistant Prostate Cancer: Risk Factors and Practical Considerations.镭-223 治疗去势抵抗性前列腺癌骨转移的血液学毒性：危险因素与实际考虑。
Clin Genitourin Cancer. 2018 Aug;16(4):e919-e926. doi: 10.1016/j.clgc.2018.03.007. Epub 2018 Mar 23.
9
Prostate cancer - Therapy with radium-223.前列腺癌——镭-223治疗
Rev Assoc Med Bras (1992). 2017 Dec;63(12):1019-1023. doi: 10.1590/1806-9282.63.12.1019.
10
Radium-223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer Cells and Bone Microenvironment in Mouse Models.镭-223 通过双重靶向癌细胞和小鼠模型中的骨微环境抑制前列腺癌骨转移。
Clin Cancer Res. 2017 Aug 1;23(15):4335-4346. doi: 10.1158/1078-0432.CCR-16-2955. Epub 2017 Mar 31.

引用本文的文献

1
Acute Promyelocytic Leukemia After Radium-223 Exposure for Prostate Cancer in a Chemotherapy-Naïve Patient.一名未接受过化疗的前列腺癌患者在接受镭-223治疗后发生急性早幼粒细胞白血病。
Nucl Med Mol Imaging. 2020 Oct;54(5):256-260. doi: 10.1007/s13139-020-00652-9. Epub 2020 Jul 9.
2
Ecotropic viral integration site 1 regulates the progression of acute myeloid leukemia via MS4A3-mediated TGFβ/EMT signaling pathway.嗜亲性病毒整合位点1通过MS4A3介导的TGFβ/EMT信号通路调节急性髓系白血病的进展。
Oncol Lett. 2018 Aug;16(2):2701-2708. doi: 10.3892/ol.2018.8890. Epub 2018 Jun 4.